- Home
- UTHR vs HPQ Comparison
UTHR vs HPQ Comparison
Compare UTHR & HPQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- HPQ
- Stock Information
- Founded
- UTHR 1996
- HPQ 1939
- Country
- UTHR United States
- HPQ United States
- Employees
- UTHR N/A
- HPQ N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- HPQ Computer Manufacturing
- Sector
- UTHR Health Care
- HPQ Technology
- Exchange
- UTHR Nasdaq
- HPQ Nasdaq
- Market Cap
- UTHR 20.7B
- HPQ 23.5B
- IPO Year
- UTHR 1999
- HPQ N/A
- Fundamental
- Price
- UTHR $448.47
- HPQ $26.90
- Analyst Decision
- UTHR Buy
- HPQ Hold
- Analyst Count
- UTHR 15
- HPQ 12
- Target Price
- UTHR $459.60
- HPQ $30.29
- AVG Volume (30 Days)
- UTHR 846.4K
- HPQ 10.1M
- Earning Date
- UTHR 10-29-2025
- HPQ 11-25-2025
- Dividend Yield
- UTHR N/A
- HPQ 4.29%
- EPS Growth
- UTHR 17.94
- HPQ N/A
- EPS
- UTHR 25.63
- HPQ 2.76
- Revenue
- UTHR $3,077,800,000.00
- HPQ $54,711,000,000.00
- Revenue This Year
- UTHR $13.71
- HPQ $3.86
- Revenue Next Year
- UTHR $5.72
- HPQ $1.37
- P/E Ratio
- UTHR $17.38
- HPQ $9.77
- Revenue Growth
- UTHR 17.62
- HPQ 2.61
- 52 Week Low
- UTHR $266.98
- HPQ $21.21
- 52 Week High
- UTHR $459.48
- HPQ $39.80
- Technical
- Relative Strength Index (RSI)
- UTHR 65.25
- HPQ 45.90
- Support Level
- UTHR $415.00
- HPQ $26.20
- Resistance Level
- UTHR $459.40
- HPQ $27.29
- Average True Range (ATR)
- UTHR 13.47
- HPQ 0.64
- MACD
- UTHR -1.34
- HPQ -0.09
- Stochastic Oscillator
- UTHR 71.49
- HPQ 27.12
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About HPQ HP Inc.
HP (formerly Hewlett-Packard) is a behemoth in the PC and printing markets. It has focused on these markets since it exited IT infrastructure in 2015 with the split from Hewlett Packard Enterprise. HP focuses on the commercial market, but maintains sales of consumer devices and printers. The firm has a broad and global customer base, with only one third of sales coming from the US. HP completely outsources manufacturing and relies heavily on channel partners for its sales and marketing.